
Results
5
Big ticket companies showing a potential underpricing based on intrinsic value
5 companies
AstraZeneca
Market Cap: UK£234.5b
A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
AZN
UK£151.18
7D
0.9%
1Y
49.3%
GSK
Market Cap: UK£85.6b
Engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
GSK
UK£21.44
7D
-1.2%
1Y
60.4%
Haleon
Market Cap: UK£31.9b
Engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
HLN
UK£3.59
7D
-0.5%
1Y
-5.8%
Hikma Pharmaceuticals
Market Cap: UK£3.0b
Develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products.
HIK
UK£13.79
7D
4.4%
1Y
-26.8%
HUTCHMED (China)
Market Cap: UK£1.9b
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally.
HCM
UK£2.20
7D
0.9%
1Y
3.8%